Login Register Cart 0
Generic placeholder image

Reviews on Recent Clinical Trials

Editor-in-Chief

ISSN (Print): 1574-8871
ISSN (Online): 1876-1038

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Clinical Trial

Effects of Pregabalin as a Neural Pathway Inhibitor for the Treatment of Resistant Subacute and Chronic Cough: A Pilot Clinical Trials Study

Author(s): Seyed Hasan Adeli, Abolfazl Mohammad Beigi, Sajjad Ahmadpour*, Mohammad Amin Habibi, Mohammad Reza Pashaei, Ehsan Sharifipour, Mansoureh Shakeri and Akram Asghari*

Volume 18, Issue 4, 2023

Published on: 26 September, 2023

Page: [269 - 274] Pages: 6

DOI: 10.2174/0115748871262516230919070559

Price: $65

Abstract

Background: Cough hypersensitivity syndrome is one of the causes of chronic cough. Small clinical trials have suggested the effects of pregabalin as a neural pathway inhibitor in treating subacute and chronic cough resistance.

Methods: This study is an 8-week, pilot study randomized, double-blind clinical trial on 30 patients’ resistant to treatment of the underlying cause who were referred to an ultra-specialized lung clinic, Shahid Beheshti Hospital, between 2021-2022. The samples were randomly divided into control (dextromethorphan and placebo) and intervention (dextromethorphan and pregabalin). Patients were evaluated at the beginning, during, and after eight weeks of treatment, using the modified standard Leicester Cough Questionnaire (LCQ) regarding the changes and the rate of recovery compared to before Participation in the study.

Findings: The quality of life score of patients eight weeks after treatment had a significant difference and was higher in the intervention group (In the pregabalin group) than in the control group (p =0.006). The recovery rate of cough in 26% of patients was equal to 70%, but others were reported up to 50%.

Conclusion: Pregabalin increases the quality of life in patients with subacute and chronic cough resistant to standard treatment and increases the rate of recovery in these patients.

« Previous Next »
Graphical Abstract

[1]
Chung KF. Cough: Potential pharmacological developments. Expert Opin Investig Drugs 2002; 11(7): 955-63.
[http://dx.doi.org/10.1517/13543784.11.7.955] [PMID: 12084006]
[2]
Dicpinigaitis PV, Dobkin JB. Antitussive effect of the GABA-agonist baclofen. Chest 1997; 111(4): 996-9.
[http://dx.doi.org/10.1378/chest.111.4.996] [PMID: 9106580]
[3]
Francesco A, Marina A, Giuseppina B, Ernesto C, Alfredo C. Cough, a vital reflex. Mechanisms, determinants and measurements. Acta Biomed 2018; 89(4): 477-80.
[PMID: 29350663]
[4]
Mansour Ghanaie R, Fahimzad SA, Karimi A. Management of chronic cough in children. Arch Pediatr Infect Dis 2013; 1(3): 136-43.
[5]
Gibson P, Wang G, McGarvey L, et al. Treatment of unexplained chronic cough: CHEST guideline and expert panel report. Chest 2016; 149(1): 27-44.
[http://dx.doi.org/10.1378/chest.15-1496] [PMID: 26426314]
[6]
Irwin RS, Boulet LP, Cloutier MM, et al. Managing cough as a defense mechanism and as a symptom. A consensus panel report of the American College of Chest Physicians. Chest 1998; 114(2): 133S-81S.
[http://dx.doi.org/10.1378/chest.114.2_Supplement.133S] [PMID: 9725800]
[7]
Matsuda KM, Sharma D, Schonfeld AR, Kwatra SG. Gabapentin and pregabalin for the treatment of chronic pruritus. J Am Aca Dermatol 2016; 75(3): 619.
[http://dx.doi.org/10.1016/j.jaad.2016.02.1237]
[8]
Emami MH, Talaei M, Panahi Y, Saburi A, Ghanei M. Efficacy of omeprazole on cough, pulmonary function and quality of life of patients with sulfur mustard lung injury: A placebo-control, cross-over clinical trial study. J Res Med Sci: Official J Isfahan Univ Med Sci 2014; 19(11): 1027.
[9]
Tassone DM, Boyce E, Guyer J, Nuzum D. Pregabalin: A novel γ-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 2007; 29(1): 26-48.
[http://dx.doi.org/10.1016/j.clinthera.2007.01.013] [PMID: 17379045]
[10]
Mahoori A, Hassani E, Karami N, Azizpoure M. Comparison of gabapentin, pregabalin and placebo as premedication for attenuation of hemodynamic response to laryngoscopy and endotracheal intubation. Tehran Univ Med J TUMS Pub 2017; 75(5): 367-73.
[11]
Van de Kerkhove C, Goeminne PC, Van Bleyenbergh P, Dupont LJ. A cohort description and analysis of the effect of gabapentin on idiopathic cough. Cough 2012; 8(1): 9.
[http://dx.doi.org/10.1186/1745-9974-8-9] [PMID: 23114102]
[12]
Vertigan AE, Kapela SL, Ryan NM, Birring SS, McElduff P, Gibson PG. Pregabalin and speech pathology combination therapy for refractory chronic cough: A randomized controlled trial. Chest 2016; 149(3): 639-48.
[http://dx.doi.org/10.1378/chest.15-1271] [PMID: 26447687]
[13]
Li J, Ye L. Effect of pregabalin for the treatment of chronic refractory cough. Medicine 2019; 98(23): e15916.
[http://dx.doi.org/10.1097/MD.0000000000015916] [PMID: 31169707]
[14]
Al-Sheklly B, Badri H, Satia I, Woodcock A, Smith J. The use of gabapentin and pregabalin for the management of chronic cough in a tertiary cough clinic. BMJ Publishing Group Ltd 2017.
[http://dx.doi.org/10.1136/thoraxjnl-2017-210983.248]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy